Figure 1.
Figure 2.
Transplant related characteristics
| Characteristic | Number | Percentage/range |
|---|---|---|
| ECOG | ||
| 0 | 33 | 100% |
| HCT-CI | ||
| 0 | 32 | 97% |
| 1 | 1 | 3.0% |
| Stem cell mobilization | ||
| G-CSF | 14 | 42.4% |
| Cyclophosphamide with G-CSF | 12 | 36.4% |
| G-CSF with plerixafor | 7 | 21.2% |
| Mean CD34 Count (106/kg) | 6.77 | 1 – 17.3 × 106/kg |
| Conditioning Regimen | ||
| Be-EAM | 29 | 87.9% |
| BEAM | 4 | 12.1% |
| Median Neutrophil engraftment (days) | 12 | 10–43 days |
| Median Platelet engraftment (days) | 16 | 11–45 days |
| Toxicities | ||
| Mucositis | ||
| Grade I | 14 | 42.4% |
| Grade II | 11 | 33.3% |
| Grade III | 4 | 12.1% |
| Grade IV | 2 | 6.1% |
| Diarrhea | 25 | 75.8% |
| Gastrointestinal bleeding | 3 | 9.1% |
| Post-transplant relapse | ||
| In less than Three months | 2 | 6.1% |
| Three to Twelve months | 6 | 18.2% |
| More than Twelve months | 6 | 18.2% |
| Post-transplant CR | 20 | 60.6% |
| Cause of death | ||
| Sepsis | 4 | 12.1% |
| Disease progression | 3 | 9.1% |
| COVID-19 | 1 | 3.0% |
| Primary graft failure | 2 | 6.1% |
Univariate analysis for overall survival and progression-free survival
| Variable | Overall Survival | Progression-Free Survival | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Extranodal on relapse | 0.50 (0.13–1.94) | 0.318 | 1.50 (0.61–3.70) | 0.382 |
| Be-EAM conditioning | 0.14 (0.04–0.53) | 0.004 | 0.39 (0.13–1.20) | 0.102 |
| More than 24 months from diagnosis to transplant | 0.27 (0.05–1.36) | 0.112 | 0.51 (0.18–1.44) | 0.204 |
| Bulky disease | 0.35 (0.03–3.62) | 0.378 | 0.63 (0.13–3.01) | 0.560 |
| Nodular sclerosis | 0.85 (0.24–2.99) | 0.795 | 1.08 (0.44–2.66) | 0.873 |
| Age more than or equal 30 years | 0.92 (0.23–3.61) | 0.905 | 1.10 (0.42–2.91) | 0.840 |
| Pre-transplant >1 salvage | 1.73 (0.44–6.78) | 0.432 | 0.57 (0.17–1.96) | 0.371 |
| Primary refractory | 2.08 (0.59–7.33) | 0.257 | 1.41 (0.56–3.53) | 0.461 |
| Advanced stage on relapse | 2.61 (0.65–10.44) | 0.174 | 1.87 (0.73–4.79) | 0.192 |
| Pre-transplant less than CR | 3.69 (1.03–13.23) | 0.045 | 1.38 (0.53–3.55) | 0.510 |
| Post-transplant less than CR | 3.87 (0.99–15.11) | 0.051 | 5.06 (1.95–13.15) | <0.001 |
| Pre-transplant relapse in less than 12 months | 4.02 (1.00–16.08) | 0.049 | 1.13 (0.45–2.81) | 0.792 |
Patient characteristics_
| Characteristic | Number (range) | Percentage |
|---|---|---|
| Male | 21 | 63.6% |
| Female | 12 | 36.4% |
| B-symptoms | ||
| Diagnosis | 26 | 78.8% |
| Relapse | 13 | 39.4% |
| Bulky disease at relapse | 3 | 9.1% |
| Histological subtype | ||
| Nodular Sclerosis | 16 | 48.5% |
| Mixed Cellularity | 6 | 18.2% |
| Lymphocyte Rich | 2 | 6.1% |
| Unspecified cHL | 9 | 27.2% |
| Ann Arbor stage (at diagnosis) | ||
| II | 8 | 24.3% |
| III | 14 | 42.4% |
| IV | 11 | 33.3% |
| Ann Arbor stage (at relapse) | ||
| I | 6 | 18.2% |
| II | 8 | 24.2% |
| III | 12 | 36.4% |
| IV | 7 | 21.2% |
| Extranodal Disease | ||
| Diagnosis | 5 | 15.2% |
| Relapse | 14 | 42.4% |
| Bone marrow involvement (at diagnosis) | 7 | 21.2% |
| Duration of CR1 | ||
| < 12 months | 16 | 48.5% |
| ≥ 12 months | 17 | 51.5% |
| First salvage therapy | ||
| DHAP | 12 | 36.4% |
| ICE | 6 | 18.2% |
| IGEV | 5 | 15.1% |
| GDP | 2 | 6.1% |
| Brentuximab-Bendamustine | 7 | 21.2% |
| ESHAP | 1 | 3.0% |
| Brentuximab | ||
| Pre-transplant | 10 | 30.3% |
| Post-transplant | 4 | 12.1% |
| Pre-transplant disease status | ||
| CR | 24 | 72.7% |
| PR | 9 | 27.3% |
| Relapsed disease | 19 | 57.6% |
| Primary refractory disease | 14 | 42.4% |